Optum Rx shifts to transparent fees

Pharmacy benefit managers sit in the middle of the drug-buying system. They decide which medicines get preferred coverage, negotiate with drugmakers, and shape what employers, insurers, pharmacies, and patients pay. The problem is that the money flow has long been hard to see — especially when PBM profits rise with a drug’s list price. That is the part Optum Rx says it is now changing. ### What did Optum Rx actually announce? On May 11, Optum Rx said it is rolling out a new pharmacy care model that replaces pricing tied to manufacturer-set drug prices or prescription volume with a transparent, fee-based structure for every PBM customer. In plain English, Optum says it wants clients to know what it gets paid, what comes from drugmakers, and what gets passed through. ### Why is “profits won’t depend on drug prices” such a big deal? Because that has been the core criticism of the PBM business for years. If a middleman earns more when a drug’s sticker price is higher, buyers naturally wonder whether everyone’s incentives are backward. Optum’s pitch is that its compensation should no longer rise just because a manufacturer posts a bigger list price. Bloomberg framed the move exactly that way — a shift away from having profits linked to medication list prices. (unitedhealthgroup.com) ### What changes for employers and health plans? The main promise is visibility. Optum says clients will get more direct clarity into manufacturer payments and a simpler fee structure instead of a mess of spread pricing, retained rebates, and hard-to-compare contract terms. Modern Healthcare says the company is explicitly trying to give clients a clearer view into the money it receives from drugmakers. That matters because employers and insurers are the ones footing most of the pharmacy bill, but they often struggle to audit how much value the PBM actually kept. (bloomberg.com) ### What changes for patients? Optum is also promising consumer-facing tools — basically, more prescription-level price visibility before a fill happens. The company says the model includes affordability tools for consumers, and Modern Healthcare says the effort is meant to show prescription-level cost estimates to payers and patients. That does not mean drug prices suddenly get cheap. But it does mean fewer black-box moments where a patient only learns the real cost at the pharmacy counter. (modernhealthcare.com) ### How big is Optum Rx here? Very big. Bloomberg says Optum Rx handled about 1.7 billion prescriptions last year. That scale matters because this is not a niche startup trying a cleaner contract model. This is one of the three dominant PBMs saying the old way has become too politically and commercially costly to defend. (unitedhealthgroup.com) ### Why now? Pressure has been building from three directions at once — employers want cleaner contracts, regulators want more disclosure, and PBMs have already been losing some old revenue streams. STAT noted earlier this year that proposed federal transparency rules would force far more disclosure to employer clients, and other 2026 reforms have targeted PBM payment structures in Medicare. Modern Healthcare also reported in March that PBMs were already hunting for replacement fee income as traditional rebate economics weakened. (bloomberg.com) ### Does this fix the PBM problem? Not by itself. A transparent fee model can make incentives easier to inspect, but the catch is that “transparent” in healthcare often means clearer contracts, not necessarily lower total spending. The real test is whether clients can verify pass-through economics, whether patients see lower out-of-pocket costs, and whether competitors feel forced to match the model in substance rather than branding. (statnews.com) ### Bottom line This is a defensive move, but also a real market signal. Optum Rx is saying the old PBM formula — opaque rebates, list-price-linked economics, and trust us on the math — is getting harder to sell. If one of the biggest players now thinks transparency is the safer business model, the rest of the market will have to answer that. (unitedhealthgroup.com)